LSA
VKTX icon

Leonteq Securities AG’s Viking Therapeutics VKTX Stock Holding History

Leonteq Securities AG’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$603K Sell
15,457
-7,355
-32% -$238K 0.02% 363
2026
Q1 		$742K Buy
22,812
+8,951
+65% +$288K 0.03% 339
2025
Q4 		$488K Sell
13,861
-294
-2% -$10.4K 0.01% 469
2025
Q3 		$372K Buy
14,155
+4,549
+47% +$136K 0.01% 468
2025
Q2 		$255K Sell
9,606
-6,041
-39% -$159K 0.01% 514
2025
Q1 		$375K Buy
15,647
+4,279
+38% +$135K 0.02% 414
2024
Q4 		$457K Buy
11,368
+3,309
+41% +$189K 0.03% 376
2024
Q3 		$510K Buy
8,059
+3,655
+83% +$214K 0.04% 321
2024
Q2 		$233K Buy
4,404
+1,346
+44% +$88.2K 0.02% 449
2024
Q1 		$251K Buy
3,058
+2,958
+2,958% +$132K 0.02% 457
2023
Q4 		$1.86K Buy
+100
New +$1.31K ﹤0.01% 1124

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Leonteq Securities AG's VKTX Position: Q2 2026 in Review

Leonteq Securities AG reduced its Viking Therapeutics (VKTX) stake by 32% in Q2 2026, selling an estimated $238K and leaving 15,457 shares worth $603K. The position accounts for 0.02% of the portfolio, ranked #363.

Leonteq Securities AG first reported a position in VKTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $742K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Leonteq Securities AG held 15,457 shares of Viking Therapeutics worth $603K as of Q2 2026.
  • Leonteq Securities AG sold 7,355 Viking Therapeutics shares in Q2 2026, an estimated $238K.
  • Viking Therapeutics made up 0.02% of Leonteq Securities AG's portfolio in Q2 2026, its #363 holding.
  • Leonteq Securities AG first reported a position in Viking Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Leonteq Securities AG's Viking Therapeutics position peaked at $742K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.